Acute kidney injury: Difference between revisions

From IDWiki
No edit summary
Β 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
βˆ’
==Definition==
+
==Background==
   
 
*An inability of the kidneys to maintain body homeostasis, usually defined by an acute increase in creatinine
 
*An inability of the kidneys to maintain body homeostasis, usually defined by an acute increase in creatinine
  +
*Novel biomarkers are under development to complement creatinine, and are generally classified into:
  +
**Stress markers
  +
**Damage markers
  +
**Functional markers, including cystatin C
   
βˆ’
==AKIN Stage==
+
=== KDIGO Staging ===
βˆ’  
 
{| class="wikitable"
 
{| class="wikitable"
 
!Stage
 
!Stage
βˆ’
!Serum creatinine
+
!Serum Creatinine
  +
!Urine Output
βˆ’
!Or, urine output
 
 
|-
 
|-
 
|1
 
|1
βˆ’
|Creatinine increase β‰₯26.5 umol/L or 1.5-2 times baseline
+
|1.5 to 1.9 times baseline, or
  +
β‰₯26.5 ΞΌmol/L increase
βˆ’
|<0.5ml/kg/h for 6h
+
|<0.5 mL/kg/h for 6-12 hours
 
|-
 
|-
 
|2
 
|2
βˆ’
|Creatinine increase 2-3 times baseline
+
|2 to 2.9 times baseline
βˆ’
|&lt;0.5ml/kg/h for 12h
+
|<0.5 mL/kg/h for β‰₯12 hours
 
|-
 
|-
 
|3
 
|3
βˆ’
|Creatinine increase &gt;3 times baseline, or creatinine β‰₯354 umol/L increased by at least 44 umol/L, or need for dialysis
+
|3 times baseline, or β‰₯353.6 ΞΌmol/L, or started renal replacement therapy
βˆ’
|&lt;0.3ml/kg/h for 24h
+
|<0.3 mL/kg/h for β‰₯24 hours, or anuria for β‰₯12 hours
 
|}
 
|}
   
Line 26: Line 30:
   
 
*Pre-renal: decreased renal perfusion
 
*Pre-renal: decreased renal perfusion
βˆ’
**Hypovolemia
+
**[[Hypovolemia]]
βˆ’
**Blood loss
+
**[[Blood loss]]
βˆ’
**Shock
+
**[[Shock]]
βˆ’
**Sepsis
+
**[[Sepsis]]
βˆ’
**Heart failure
+
**[[Heart failure]]
βˆ’
**Vomiting and diarrhea
+
**[[Vomiting]] and [[diarrhea]]
 
*Renal/intrinsic
 
*Renal/intrinsic
βˆ’
**Glomerulonephritis (GN): glomerular damage
+
**[[Glomerulonephritis]] (GN): glomerular damage
 
***Primary
 
***Primary
 
****Minimal change (in children)
 
****Minimal change (in children)
Line 40: Line 44:
 
***Secondary
 
***Secondary
 
****Focal sclerosing or diffuse (in diabetic patients)
 
****Focal sclerosing or diffuse (in diabetic patients)
βˆ’
****Lupus, multiple myeloma, and amyloidosis
+
****[[Lupus]], [[multiple myeloma]], and [[amyloidosis]]
βˆ’
**Acute tubular necrosis (ATN): tubular damage
+
**[[Acute tubular necrosis]] (ATN): tubular damage
βˆ’
***Ischemia from prerenal disease
+
***[[Ischemia]] from prerenal disease
 
***Toxins
 
***Toxins
 
***Drugs
 
***Drugs
βˆ’
****Aminoglycosides
+
****[[Aminoglycosides]]
βˆ’
****Amphotericin
+
****[[Amphotericin B|Amphotericin]]
βˆ’
****Cisplatin
+
****[[Cisplatin]]
 
***Pigments: hemoglobin, myoglobin
 
***Pigments: hemoglobin, myoglobin
βˆ’
***Proteins: immunoglobulin light chains (e.g. multiple myeloma)
+
***Proteins: immunoglobulin light chains (e.g. [[multiple myeloma]])
 
***Crystals
 
***Crystals
βˆ’
****Uric acid
+
****[[Gout|Uric acid]]
βˆ’
****Acyclovir
+
****[[Acyclovir]]
βˆ’
****Methotrexate
+
****[[Methotrexate]]
βˆ’
****Indinavir
+
****[[Indinavir]]
βˆ’
****Oral NaPO4
+
****Oral sodium phosphate
 
***Contrast-induced
 
***Contrast-induced
βˆ’
**Acute interstitial nephritis (AIN): interstitial damage
+
**[[Acute interstitial nephritis]] (AIN): interstitial damage
 
***Allergic
 
***Allergic
βˆ’
****Antibiotics: beta-lactams, sulfas
+
****Antibiotics: [[Ξ’-lactams|beta-lactams]], [[sulfonamides]]
βˆ’
****NSAIDs
+
****[[NSAID]]
βˆ’
****PPIs
+
****[[PPI]]
 
***Infective
 
***Infective
βˆ’
****Pyelonephritis
+
****[[Pyelonephritis]]
βˆ’
****Legionellosis
+
****[[Legionellosis]]
 
***Infiltration
 
***Infiltration
βˆ’
****Sarcoidosis
+
****[[Sarcoidosis]]
βˆ’
****Lymphoma
+
****[[Lymphoma]]
βˆ’
****Leukemia
+
****[[Leukemia]]
 
***Autoimmune
 
***Autoimmune
βˆ’
****SjΓΆgren's syndrome
+
****[[SjΓΆgren syndrome]]
βˆ’
****TINU syndrome
+
****[[TINU syndrome]]
βˆ’
****IgG4 disease
+
****[[IgG4 disease]]
βˆ’
****Systemic lupus erythematosis (SLE)
+
****[[Systemic lupus erythematosus]]
 
***Small vessel disease
 
***Small vessel disease
 
****Cholesterol emboli
 
****Cholesterol emboli
βˆ’
****Thrombotic microangiopathy
+
****[[Thrombotic microangiopathy]]
βˆ’
*****HUS/TTP
+
*****[[HUS]]/[[TTP]]
βˆ’
*****DIC
+
*****[[DIC]]
βˆ’
*****Preeclampsia
+
*****[[Preeclampsia]]
βˆ’
*****Anti-phospholipid syndrome (APS)
+
*****[[Anti-phospholipid syndrome]] (APS)
βˆ’
*****Malignant hypertension
+
*****[[Malignant hypertension]]
βˆ’
*****Scleroderma renal crisis
+
*****[[Scleroderma renal crisis]]
 
*Post-renal (obstructive)
 
*Post-renal (obstructive)
 
**Bladder neck
 
**Bladder neck
βˆ’
***BPH or prostate cancer (in men)
+
***[[BPH]] or [[prostate cancer]] (in men)
βˆ’
***Cervical cancer (in women)
+
***[[Cervical cancer]] (in women)
βˆ’
**Neurogenic bladder
+
**[[Neurogenic bladder]]
βˆ’
***Anticholinergics
+
***[[Anticholinergics]]
 
**Ureteral (bilateral)
 
**Ureteral (bilateral)
βˆ’
***Malignancy
+
***[[Malignancy]]
  +
***[[Lymphadenopathy]]
βˆ’
***LAN
 
βˆ’
***Retroperitoneal fibrosis
+
***[[Retroperitoneal fibrosis]]
βˆ’
***Nephrolithiasis
+
***[[Nephrolithiasis]]
   
 
==Clinical Manifestations==
 
==Clinical Manifestations==
   
βˆ’
===Clinical clues of etiology===
+
===Clinical Clues of Etiology===
   
 
{| class="wikitable"
 
{| class="wikitable"
  +
!
 
!Type
 
!Type
 
!History
 
!History
 
!Examination
 
!Examination
 
|-
 
|-
βˆ’
|Prerenal
+
| colspan="2" |Prerenal
 
|Volume loss (e.g. vomiting, diarrhea, diuretics, hemorrhage, burns)<br />Thirst and reduced fluid intake<br />Heart failure or cirrhosis
 
|Volume loss (e.g. vomiting, diarrhea, diuretics, hemorrhage, burns)<br />Thirst and reduced fluid intake<br />Heart failure or cirrhosis
 
|Weight loss, orthostatic hypotension and tachycardiac, poor skin turgor, signs of heart failure or liver failure
 
|Weight loss, orthostatic hypotension and tachycardiac, poor skin turgor, signs of heart failure or liver failure
 
|-
 
|-
βˆ’
|Intrinsic renal
+
| rowspan="4" |Intrinsic renal
βˆ’
|
 
βˆ’
|
 
βˆ’
|-
 
 
|ATN
 
|ATN
 
|History of nephrotoxic medications, hypotension, trauma or myalgias suggestion rhabdo, CT contrast
 
|History of nephrotoxic medications, hypotension, trauma or myalgias suggestion rhabdo, CT contrast
Line 128: Line 130:
 
|Livedo reticularis, fundoscopy showing malignant hypertension, abdominal bruits
 
|Livedo reticularis, fundoscopy showing malignant hypertension, abdominal bruits
 
|-
 
|-
βˆ’
|Post-renal
+
| colspan="2" |Post-renal
 
|Urinary urgency or hesitancy, gross hematuria, polyuria, stones, medications, cancer
 
|Urinary urgency or hesitancy, gross hematuria, polyuria, stones, medications, cancer
 
|Bladder distension, pelvic mass, prostate enlargement
 
|Bladder distension, pelvic mass, prostate enlargement

Latest revision as of 22:04, 9 October 2022

Background

  • An inability of the kidneys to maintain body homeostasis, usually defined by an acute increase in creatinine
  • Novel biomarkers are under development to complement creatinine, and are generally classified into:
    • Stress markers
    • Damage markers
    • Functional markers, including cystatin C

KDIGO Staging

Stage Serum Creatinine Urine Output
1 1.5 to 1.9 times baseline, or

β‰₯26.5 ΞΌmol/L increase

<0.5 mL/kg/h for 6-12 hours
2 2 to 2.9 times baseline <0.5 mL/kg/h for β‰₯12 hours
3 3 times baseline, or β‰₯353.6 ΞΌmol/L, or started renal replacement therapy <0.3 mL/kg/h for β‰₯24 hours, or anuria for β‰₯12 hours

Differential Diagnosis

Clinical Manifestations

Clinical Clues of Etiology

Type History Examination
Prerenal Volume loss (e.g. vomiting, diarrhea, diuretics, hemorrhage, burns)
Thirst and reduced fluid intake
Heart failure or cirrhosis
Weight loss, orthostatic hypotension and tachycardiac, poor skin turgor, signs of heart failure or liver failure
Intrinsic renal ATN History of nephrotoxic medications, hypotension, trauma or myalgias suggestion rhabdo, CT contrast Muscle tenderness, compartment syndrome, volume status
GN Lupus, systemic sclerosis, rash, arthritis, uveitis, weight loss, fatigue, HCV infection, HIV infection, hematuria, foamy urine, cough, sinusitis, hemoptysis Periorbital, sacral, and lower-extremity edema; rash; oral or nasal ulcers
AIN Medication use (antiiotics, PPIs), rash, arthralgias, fever, infection Fever, drug rash
Vascular Nephrotic syndrome, trauma, flank pain, anticoagulation, vascular surgery Livedo reticularis, fundoscopy showing malignant hypertension, abdominal bruits
Post-renal Urinary urgency or hesitancy, gross hematuria, polyuria, stones, medications, cancer Bladder distension, pelvic mass, prostate enlargement

Source: Rahman M, Shad F, and Smith MC. Acute kidney injury: A guide to diagnosis and management. Am Fam Physician. 2012;86(7):631-639.

Investigations

  • Laboratory
    • Urinalysis and microscopy
      • Granular casts (from heme), suggesting ATN
      • Red blood cell casts, suggesting GN
    • Urine sodium
      • <10mmol/L suggests pre-renal, unless diuresed
    • Urea to creatinine ratio
      • Increased ratio suggests pre-renal cause
    • Extended electrolytes
  • Renal ultrasound, for possible obstruction

Fractional excretion of sodium (FENa)

$FENa = \frac{U_{Na} \div U_{Cr}}{S_{Na} \div S_{Cr}} = \frac{U_{Na} \times S_{Cr}}{S_{Na} \times U_{Cr}}$

FENa Etiology
<1% Pre-renal
1 to 4%
>2%
Intrinsic renal
Acute tubular necrosis (ATN)
>4% Post-obstructive

Management

  • Treatment depends on etiology
    • Prerenal: Fluid challenge
    • Renal: Stop nephrotoxic medications
    • Post-renal: Nephrostomy tubes
  • Dialysis if
    • Acidosis
    • Electrolyte imbalance (K+)
    • Intoxication (drugs, alcohols)
    • Overloaded fluid (heart failure)
    • Uremia (pericarditis, neurological symptoms)

Prognosis

  • Increased risk of developing CKD with
    • Increasing age
    • Female sex
    • AKIN stage
    • Absolute increase in serum creatinine
    • Albuminuria